COVID-19 Sürecinde İbuprofen ve Diğer Nonsteroidal Antienflamatuvar İlaçların Kullanımının Güvenirliliği

Dünya Sağlık Örgütü (DSÖ) Çin Ülke Ofisi 31 Aralık 2019'da Çin'in Hubei eyaletinin Wuhan şehrinde etiyolojisi bilinmeyen pnömoni vakaları bildirmiştir. Bu vakaların etkeninin, daha önce insanlarda tespit edilmemiş yeni bir Coronavirus (2019-nCoV) olduğu saptanmıştır. Söz konusu virüs, 2002 yılındaki SARS enfeksiyon etkeni SARS CoV-1 virüse yakın genetik benzerliğinden dolayı SARS-CoV-2 olarak adlandırılmış, hastalığın adı da COVID-19 olarak kabul edilmiştir. Nisan 2020 itibari ile dünya üzerinde yaklaşık 3.000.000 COVID-19 vakası tespit edilmiştir. Farklı hastalıkların tedavisi için akut ya da kronik olarak kullanılan bazı ilaçların COVID-19 enfeksiyonuna duyarlılık açısından bir risk faktörü olabileceği ve/ veya COVID-19 hastalığının seyri üzerinde olumsuz etkilere sahip olabileceği yönündeki preklinik bulgular ya da hipotez düzeyindeki öneriler bu ilaçları kullanan kişilerde tedirginlik yaratmıştır. Bahsi geçen ilaçlar arasında, non-steroidal Antienflamatuvar grubu bir ilaç olan İbuprofen de yer almıştır. COVID-19 enfeksiyon etkenine duyarlılığı arttırdığı ve/ veya COVID-19 hastalığının seyri üzerinde olumsuz etkilere sahip olabileceği iddia edilen ilaçların klinik açıdan dikkatle değerlendirilmesi ve yeterli bilimsel kanıtlar çerçevesinde olaya netlik kazandırılması son derece önemlidir.

Anahtar Kelimeler:

SARS-CoV-2, COVID-19, NSAII, Ibuprofen, akılcı ilaç kullanımı

COVID-19 and Safety of Ibuprofen and Other a Non-steroidal Antiinflammatory Drugs

On 31st December 2019, World Health Organization (WHO) Country Office in China reported pneumonia cases of unknown etiology in Wuhan in the Hubei province of the Republic of China. It is reported that a novel coronavirus 2019 (2019-nCoV), has not been previously identified in humans, causes the infectious disease, known as COVID-19. 2019-nCoV virus renamed as SARS-CoV-2 virus which is genetically similar to the SARS Coronavirus of 2002, SARS-CoV-1. As of April 2020 approxy3 million people confirmed as COVID-19 positive, globally. Based on preclinical evidences and/or limited clinical reports, it is hypothesised that some pharmacological agents, including Ibuprofen, a Non-steroidal antiinflammatory drug, increase the risk of onset anddeveloping severe COVID-19, and exacerbate the symptoms in patients. More definite evidence from laboratory and clinical research is needed for further progress in order enlighten this issue.

Keywords:

SARS-CoV-2, COVID-19, NSAID, Ibuprofen, rational drug use,

PDF

___

1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Mar 11. pii: S2213-2600(20)30116-8. doi: 10.1016/S2213-2600(20)30116-8.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. SARS- CoV2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1-10.
3. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. Susceptibility to SARS coronavirus S protein- driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun. 2004;319:1216-21.
4. Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med.2020 Mar 18. pii:taaa041. doi: 10.1093/jtm/taaa041.
5. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https:// www.escardio.org/Councils/Council-onHypertension (CHT)/News/position-statementof-the-esc-council-on-hypertension-on-aceinhibitors-and-ang. Accessed March 20, 2020.
6. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020;368:m1086.
7. K. Willsher, Anti-inflammatories may aggravate Covid-19, France advises, The Guardian (2020).
8. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/ news/ema-gives-advice-use-non-steroidal-antiinflammatories-covid-19 (Accessed on March 19, 2020).
9. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms. Science Alert 2020. https://www.sciencealert. com/who-recommends-to-avoid-takingibuprofen-for-covid-19-symptoms (Accessed on March 19, 2020).
10. Fitzgerald GA. Misguided drug advice for COVID-19 Science 27 Mar 2020: Vol. 367, Issue 6485, pp. 1434DOI: 10.1126/ science.abb8034
11. Vijay R., Fehr AR, Janowski AM et al. Virusinduced inflammasome activation is suppressed by prostaglandin D2/DP1 signaling. Proc. Natl. Acad. Sci. U.S.A. 2017;114:E5444.
12. Yan, X., Hao, Q., Mu, Y., et al. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int J Biochem Cell Biol 2006;38:1417-28.
13. Amici C, Di Caro A, Ciucci A., et al. Indomethacin has a potent antiviral activity against SARS coronavirus Antiviral Therapy 2006:11;1021–1030.
14. Little P. Non-steroidal anti-inflammatory drugs and covid-19 BMJ 2020;368:m1185 doi: 10.1136/ bmj.m1185